
    
      This is a single-arm, non-randomized Phase II trial of DLPC-9NC administered by aerosol 5
      consecutive days per week for 8 weeks every 10 weeks.

      Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day)
      per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks.

      Patients that have a resectable lung cancer will only receive one course of treatment and
      will be operated on about two weeks after completing the 8-week course.
    
  